Article Information
- Received May 20, 2022
- Revision received October 31, 2022
- Accepted November 12, 2022
- First published November 28, 2022.
- Version of record published January 18, 2023.
Author Information
- Gessynger Morais-Silva1,2,3,*,
- Rianne R. Campbell1,*,
- Hyungwoo Nam1,
- Mahashweta Basu4,5,
- Marco Pagliusi1,6,
- Megan E. Fox1,
- C. Savio Chan7,
- Sergio D. Iñiguez8,
- Seth Ament4,5,
- Nathan Cramer1,
- Marcelo Tadeu Marin2,3, and
- Mary Kay Lobo1
- 1Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland 21201
- 2Sao Paulo State University (UNESP), School of Pharmaceutical Sciences, Laboratory of Pharmacology, Araraquara, Sao Paulo 14800903, Brazil
- 3Joint Graduate Program in Physiological Sciences, Federal University of São Carlos/Sao Paulo State University, CEP 13565-905, São Carlos/Araraquara, Brazil
- 4Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21201
- 5Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland 21201
- 6Department of Structural and Functional Biology, State University of Campinas, SP-13083-872, Campinas, Brazil
- 7Department of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611
- 8Department of Psychology, University of Texas at El Paso, El Paso, Texas 79902
Author contributions
Author contributions: G.M.-S., M.T.M., and M.K.L. designed research; G.M.-S., R.R.C., H.N., M.B., M.P., M.E.F., S.A., and N.C. performed research; M.E.F., C.S.C., and S.D.I. contributed unpublished reagents/analytic tools; G.M.-S., R.R.C., H.N., M.B., M.P., M.E.F., S.A., N.C., and M.K.L. analyzed data; G.M.-S., H.N., and M.K.L. wrote the paper.
↵*G.M.-S. and R.R.C. contributed equally to this work.
Disclosures
- Received May 20, 2022.
- Revision received October 31, 2022.
- Accepted November 12, 2022.
This work was supported by National Institutes of Health Grants R01-MH-106500, R01-DA-038613, and R01-DA-047843 to M.K.L., and R01-NS-069777 and R01-MH-112768 to C.S.C.; Grants 2015/25308-3 and 2018/05496-8 from São Paulo Research Foundation (FAPESP) to G.M.-S.; and financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil (CAPES; Finance Code 001). FAPESP and CAPES had no further role in the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.
The authors declare no competing financial interests.
- Correspondence should be addressed to Mary Kay Lobo at mklobo{at}som.umaryland.edu
Funding
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
2015/25308-3; 2018/05496-8HHS | NIH | National Institute of Mental Health (NIMH)
R01MH106500; R01MH112768HHS | NIH | National Institute on Drug Abuse (NIDA)
R01DA038613; R01DA047843HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
R01NS069777Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Code 001
Other Version
- previous version (November 28, 2022).
- You are viewing the most recent version of this article.
